Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.
This is an Open Phase II Clinical Study of Tislelizumab Combined with Lenvatinib and GEMOX Versus Tislelizumab Combined with GEMOX in the Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer.
Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
DRUG: tislelizumab+lenvatinib+GMOX|DRUG: tislelizumab+GEMOX
Objective response rate (ORR), 6 months
Progression-free survival (PFS), 18 months|Overall survival (OS), 24 months|R0 resection rate, 6 months|AE, Improvement in quality of life as measured by the EORTC Quality of Life Questionnaire QLQ-C30 (V3.0), 24 months
This is an Open Phase II Clinical Study of Tislelizumab Combined with Lenvatinib and GEMOX Versus Tislelizumab Combined with GEMOX in the Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer.